---
title: 'Director, Commercial Analytics & Information at Summit Therapeutics'
canonical: 'https://feeny.ai/job/director-commercial-analytics-information-summit-therapeutics-princeton-4sy7b3h9tjvz'
type: 'job'
last_seen: '2026-09-11'
---

# Director, Commercial Analytics & Information at Summit Therapeutics

- **Company:** Summit Therapeutics
- **Location:** Princeton, NJ
- **Compensation:** $203k–$253k
- **Posted:** 2026-09-03
- **Last confirmed live:** 2026-09-11
- **Apply:** https://job-boards.greenhouse.io/summittherapeutics/jobs/4393712009

## Job description

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

- HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

- HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

- HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

- HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Location: Princeton, NJ

Overview of Role:

The Director, Commercial Analytics & Information turns Summit's commercial data into decisions. This role owns launch analytics, performance reporting, dashboards, and the field-facing insight products that tell Sales and Marketing what is working and what is not. The role sets the definitions behind every commercial metric and is the final word on what a number means, so that Sales, Marketing, Finance, and Commercial Operations are all working from the same figure. This leader consumes the data assets owned by Commercial Data Management & Strategy and partners with Business Information on the tools that deliver analysis. Because ivonescimab is an intravenous buy-and-bill product, this role must be able to build a credible performance picture from purchase and claims data rather than from prescription data, and must be explicit about what that picture can and cannot show.

Role and Responsibilities:

- Own the commercial reporting and analytics package, including the launch dashboard, national and regional performance reporting, and the field-facing report set.
- Own the definition of every commercial metric and maintain the definitions document that Sales, Marketing, Finance, and Commercial Operations all work from.
- Build the launch analytics framework, including leading indicators that will show whether the launch is on track before revenue data can confirm it.
- Deliver analytics supporting targeting and segmentation, call planning, and field resource allocation, in partnership with Sales Operations and Marketing.
- Provide the analytical basis for incentive compensation goal setting, in partnership with Sales Operations and Finance.
- Build and maintain the analytics tooling and self-service reporting layer, in partnership with Business Information.
- Deliver insight rather than data. Explain what changed, why it changed, and what to do about it, in language a commercial leader can act on.
- Set the analytical standards the eleven Regional Business Managers work to, so regional analysis rolls up consistently.
- State clearly and in writing the limitations of the available data, including what buy-and-bill purchase data cannot tell the organization about patient-level demand.
- Collaborative Responsibilities - Market Research Support
- Apply claims, EHR, lab, and alternative data sources – including digital/omnichannel, payer, and hub – to support patient journey modeling, segmentation, and drivers-of-business analysis in partnership with Marketing.
- Leverage AI tools and analog research to surface forecast-relevant insights and support cross-functional decision making in collaboration with the Director, Forecasting and Commercial Data & Technology.
- All other duties as assigned

Experience, Education and Specialized Knowledge and Skills:

- Bachelor's degree in a quantitative, business, or life sciences field. Graduate degree preferred.
- Minimum of 10+ years of commercial analytics experience within pharmaceuticals or biotechnology industry
- Product launch analytics experience is required. Oncology launch experience is strongly preferred.
- People management experience is strongly preferred.
- Deep fluency with pharmaceutical commercial data assets, including specialty distributor and specialty pharmacy data, claims data, and patient-level data.
- Experience building performance analytics for an intravenous, buy-and-bill product is strongly preferred.
- Advanced skills in Excel, SQL, and at least one business intelligence platform such as Power BI or Tableau.
- Experience supporting incentive compensation goal setting.
- Excellent written and verbal communication skills, with a demonstrated ability to explain analytical findings simply and confidently to senior leaders.
- Ability to thrive in a fast-paced, dynamic environment and adapt to changing priorities.

This is the pay for this position

Pay Transparency $203,000—$253,000 USD

Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.

Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.

## About Summit Therapeutics

## Company Overview
- **One-liner**: Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel bispecific antibody therapies, with its lead candidate ivonescimab targeting PD-1 and VEGF for multiple solid tumors.
- **Entity Type**: Public (NASDAQ: SMMT)
- **Headquarters**: Miami, Florida, USA (with additional offices in Palo Alto, CA; Princeton, NJ; Oxford, UK; and Dublin, Ireland)
- **Founded**: 2003
- **Founders**: Not publicly disclosed on the company website; the company was founded in 2003.

## Core Business
- **Primary industry**: Biopharmaceuticals / Oncology
- **Target customers**: B2B (healthcare providers, patients, and caregivers) with a focus on resolving serious unmet medical needs in oncology
- **Mission statement**: "To resolve serious, unmet medical needs for the betterment of overall human health." [smmttx.com](https://smmttx.com/company/about-us/default.aspx)

## Products & Services
- **Ivonescimab (SMT112)**: A novel, potential first-in-class investigational bispecific antibody targeting both PD-1 and VEGF. It is designed to combine immunotherapy (PD-1 blockade) with anti-angiogenesis (VEGF blockade) into a single molecule. Currently being studied in several global Phase 3 clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC). Licensed from Akeso, Inc. (HKEX: 9926.HK) for territories including the U.S., Canada, Europe, Japan, Latin America, the Middle East, and Africa. [smmttx.com](https://smmttx.com/pipeline/default.aspx)

## Market Standing
- **Valuation/Market Cap**: Approximately $2.7 billion (as of recent data) [linkedin.com](https://www.linkedin.com/company/summit-therapeutics)
- **Key Metric**: Annual revenue of approximately $705,000 (reported). The company is pre-commercialization and heavily investing in R&D. Total funding raised since IPO (2015) is not disclosed, but the company has a strong cash position from equity offerings.
- **Notable Investors/Partners**: Akeso, Inc. (key licensing partner for ivonescimab). The company is publicly traded with institutional and retail investors.
- **Growth Signals**: 
  - Headcount grew 72.5% year-over-year to 244 employees. [linkedin.com](https://www.linkedin.com/company/summit-therapeutics)
  - Multiple global Phase 3 trials actively recruiting (HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3, ILLUMINE).
  - Over 4,000 patients have been treated with ivonescimab across all clinical trials globally. [smmttx.com](https://smmttx.com/pipeline/default.aspx)
  - Achieved Great Place to Work® Certification. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx)

## Competitive Advantages
- **Novel Mechanism**: Ivonescimab is a first-in-class bispecific antibody targeting both PD-1 and VEGF simultaneously, potentially offering superior efficacy and fewer side effects compared to combination therapies.
- **Speed and Execution**: The company emphasizes "high-speed execution in commercialization" and has rapidly initiated multiple Phase 3 trials.
- **Global Reach**: Licensed territories cover major markets (U.S., Canada, Europe, Japan, Latin America, Middle East, Africa) with a strong partner (Akeso) in the rest of the world.
- **Strong Balance Sheet**: With a $2.7B market cap and public listing, the company has access to capital markets to fund its pipeline.

## Strategic Focus
- **Current priorities**: Advancing ivonescimab through Phase 3 clinical trials across multiple solid tumor indications (NSCLC, CRC, HNSCC), with the goal of regulatory approval and commercialization.
- **Future direction**: Expanding the pipeline into additional solid tumors and leveraging the bispecific platform for future therapies. The company is focused on becoming a leading oncology player.
- **Near-term milestones**: Data readouts from ongoing Phase 3 trials, potential regulatory submissions, and building commercial infrastructure.

## Why Work Here
- **Culture**: The company has achieved Great Place to Work® Certification, indicating a positive, supportive, and fulfilling work environment. Core values include Commitment to People, Integrity, Passion for Excellence, Purposeful Urgency, Accountability, and Collaboration. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx)
- **Work Environment**: Fast-paced, high-energy atmosphere focused on innovation and collaboration. The company emphasizes "making a significant difference in patients’ lives."
- **Benefits (U.S.)**: 
  - 401(k) with 6% employer match
  - Employee Stock Purchase Plan (ESPP) with 15% discount up to the annual federal limit
  - Flexible Spending Account
  - Commuter Benefit
  - Onsite lunch provided
- **Benefits (U.K.)**: 
  - Private Medical Insurance
  - Employee Assistance Program
  - Life Assurance Policy
  - Company Pension Contributions
  - ESPP
- **Remote/Hybrid Policy**: Not explicitly stated, but multiple office locations suggest a hybrid or on-site presence is expected for many roles.
- **Open Roles**: 25 active job postings (as of recent data) including Senior Director of Sales Operations, Clinical Scientists, Medical Science Liaisons, and Drug Product MSAT roles. [greenhouse.io](https://job-boards.greenhouse.io/summitherrapeutics)
- **Headcount Growth**: 72.5% year-over-year growth signals a scaling organization with opportunities for career advancement.

## Sources
1. [smmttx.com - About Us](https://smmttx.com/company/about-us/default.aspx)
2. [smmttx.com - Investor Relations Overview](https://www.smmttx.com/overview/default.aspx)
3. [smmttx.com - Pipeline](https://smmttx.com/pipeline/default.aspx)
4. [smmttx.com - Careers Overview](https://smmttx.com/careers/careers-overview/default.aspx)
5. [linkedin.com - Summit Therapeutics Company Page](https://www.linkedin.com/company/summit-therapeutics)
6. [greenhouse.io - Summit Therapeutics Careers](https://job-boards.greenhouse.io/summitherrapeutics)

## Other roles at Summit Therapeutics

- [Senior Director, Regulatory CMC](https://feeny.ai/job/senior-director-regulatory-cmc-summit-therapeutics-united-states-qnq72sd971hr) — United States
- [National Account Director, Government Payers —Medicaid](https://feeny.ai/job/national-account-director-government-payers-medicaid-summit-therapeutics-field-1sjzqhpn2hwe) — Field, United States
- [Sr. Clinical Data Scientist](https://feeny.ai/job/sr-clinical-data-scientist-summit-therapeutics-palo-alto-y90jqt03ag43) — Palo Alto, CA
- [Sr. Manager, Clinical Quality Assurance](https://feeny.ai/job/sr-manager-clinical-quality-assurance-summit-therapeutics-remote-0mexn4fh8bg8)
- [Senior Director, Regional Marketing](https://feeny.ai/job/senior-director-regional-marketing-summit-therapeutics-princeton-nj-85z6bke8tkv2) — Princeton NJ, United States
- [Senior Manager, Commercial Analytics](https://feeny.ai/job/senior-manager-commercial-analytics-summit-therapeutics-princeton-nj-s8drfzyv2fvy) — Princeton NJ, United States
- [Associate Director, Regulatory Affairs](https://feeny.ai/job/associate-director-regulatory-affairs-summit-therapeutics-united-states-6v4qz21pkcxj) — United States
- [Chief Commercial Officer](https://feeny.ai/job/chief-commercial-officer-summit-therapeutics-princeton-nj-y6mzyr8j1web) — Princeton NJ, United States
- [Associate Director, Clinical Study Start-Up](https://feeny.ai/job/associate-director-clinical-study-start-up-summit-therapeutics-princeton-new-nemvsnpnzfdd) — Princeton New Jersey, United States
- [Senior Director, Program Management](https://feeny.ai/job/senior-director-program-management-summit-therapeutics-palo-alto-california-fwf6t8kayq3v) — Palo Alto California, United States